Fix compounding sections of Senate proposal, NCPA's CEO says

SB 959 would restrict patient access to customized medications by authorizing FDA oversight of what small pharmacies can prepare or "compound" in response to a physician's request, writes National Community Pharmacists Association CEO B. Douglas Hoey in response to a July 31 editorial stating that the bill leaves oversight of such pharmacies to states. The bill would inhibit pharmacies' ability to compound drugs to fill the void left by shortages, he writes. Hoey suggests that the Senate pass the anti-drug counterfeiting provisions of the proposal to prevent meningitis outbreaks and similar tragedies, but delay passing the sections on drug compounding until they can be revised.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC